Economic Analysis of Amifostine as Adjunctive Support for Patients with Advanced Head and Neck Cancer: Preliminary Results from a Randomized Phase II Clinical Trial from Germany-Reference-Cited by-同舟云学术

Economic Analysis of Amifostine as Adjunctive Support for Patients with Advanced Head and Neck Cancer: Preliminary Results from a Randomized Phase II Clinical Trial from Germany

Published:2001-01 Issue:2 Volume:19 Page:107-113
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Bennett Charles L.,Lane David,Stinson Tammy,Glatzel Michael,Buntzel Jens

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1081/CNV-100000145

Reference16 articles.

1. Cancer statistics, 1998

2. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer

3. Head and Neck Cancer

4. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does lower dose pilocarpine have a role in radiation-induced xerostomia in the modern radiotherapy era? A single-center experience based on patient-reported outcome measures;European Archives of Oto-Rhino-Laryngology;2024-04-04

2. Amifostine-Loaded Nanocarrier Traverses the Blood–Brain Barrier and Prevents Radiation-Induced Brain Injury;ACS Applied Materials & Interfaces;2023-03-14

3. Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review;Cancers;2022-05-16

4. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States;Journal of Managed Care & Specialty Pharmacy;2022-04

5. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy;Journal of Medical Economics;2021-11-16